Yaron Werber
Stock Analyst at TD Cowen
(2.46)
# 2,507
Out of 5,090 analysts
43
Total ratings
50%
Success rate
1.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $86 → $75 | $36.38 | +106.16% | 3 | Nov 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $44 → $51 | $44.36 | +14.97% | 3 | Nov 5, 2025 | |
| ARGX argenx SE | Maintains: Buy | $800 → $1,146 | $901.17 | +27.17% | 4 | Oct 31, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $59 → $99 | $81.68 | +21.20% | 2 | Oct 30, 2025 | |
| ALEC Alector | Downgrades: Hold | n/a | $1.22 | - | 1 | Oct 22, 2025 | |
| IOBT IO Biotech | Downgrades: Hold | n/a | $0.70 | - | 2 | Sep 30, 2025 | |
| ONC BeOne Medicines AG | Reiterates: Buy | $334 | $322.90 | +3.44% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $19.93 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $44.26 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $26.76 | - | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $153 | $205.44 | -25.53% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $132 → $122 | $96.25 | +26.75% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $27.75 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $67 | $28.13 | +138.18% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $30.87 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.71 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.40 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $29.45 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.36 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $375 → $625 | $8.42 | +7,322.80% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.92 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $31.74 | +19.72% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $20.97 | - | 1 | Oct 26, 2021 |
Ultragenyx Pharmaceutical
Nov 5, 2025
Maintains: Buy
Price Target: $86 → $75
Current: $36.38
Upside: +106.16%
Exelixis
Nov 5, 2025
Maintains: Buy
Price Target: $44 → $51
Current: $44.36
Upside: +14.97%
argenx SE
Oct 31, 2025
Maintains: Buy
Price Target: $800 → $1,146
Current: $901.17
Upside: +27.17%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $59 → $99
Current: $81.68
Upside: +21.20%
Alector
Oct 22, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.22
Upside: -
IO Biotech
Sep 30, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.70
Upside: -
BeOne Medicines AG
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $322.90
Upside: +3.44%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $19.93
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $44.26
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $26.76
Upside: -
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $205.44
Upside: -25.53%
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $96.25
Upside: +26.75%
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $27.75
Upside: -
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $28.13
Upside: +138.18%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $30.87
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.71
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $6.40
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $29.45
Upside: -
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.36
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $375 → $625
Current: $8.42
Upside: +7,322.80%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.92
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $31.74
Upside: +19.72%
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.97
Upside: -